Image of Autoimmune Myocarditis Heart Muscle Inflammation
Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

EBR Systems Inc (ASX:EBR) – which is developing the world’s only wireless cardiac pacing device for heart failure – has ticked off another important step in its progress towards entering the US$3.6 billion US market, submitting its final Premarket Approval (PMA) module to the US Food and Drug Administration.

And given the usual FDA review cycle parameters, the company anticipates approval of its WiSE CRT (Cardiac Resynchronization Therapy) System to be granted in the first quarter of CY2025, for a commercial launch sometime in the same year.

Because WiSE has been designated a ‘Breakthrough Device’, it will receive prioritised review and interactive communication with the FDA throughout the PMA process, which will involve an initial FDA-mandated filing period, followed by a substantive review which will evaluate the full PMA application.

President & Chief Executive Officer John McCutcheon said EBR was delighted to have reached this milestone.

“This submission is the result of years of effort and collaboration between our clinical, regulatory, and engineering teams,” he said.

“With this application, we are now one step closer to making WiSE available to physicians for their patients across the United States.

“If approved, this PMA package will allow us to launch WiSE in 2025. We look forward to sharing further updates as we progress through the regulatory review process.”

EBR shares moved up on the news, and at 13:53 AEST, they were trading at $1.23: a rise of 10.36% since the market opened.

EBR by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Bourse finishes week on a high as Wisetech pummeled | November 22, 2024

The ASX200 closed up 0.85% at 8,393 points. Economists increasingly expect interest rates in Australia won’t…
The Market Online Video

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing,…
Nuclear explosion mushroom cloud concept

Week 47 Wrap: HotCopper users’ most watched; Brent lifts on Putin’s scary letter; RFK dents CSL

Welcome to the end of another week. Let's start with what HotCopper users have been watching…
Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.

Dale Gillham’s weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in th…